EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival Benefit of Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hidekatsu Kuroda, Takuya Sho, Goki Suda, Masashi Ninomiya, Tamami Abe, Kei Endo, Takuya Watanabe, Yudai Fujiwara, Tokio Sasaki, Yuichi Yoshida, Keisuke Kakisaka, Takayoshi Oikawa und 20 weitere

Liver Cancer · 17.11.2026

DOI: 10.1159/lic/admag030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 17.11.2026. Verfasst von Hidekatsu Kuroda und 31 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atezolizumab plus bevacizumab (Atezo/Bev) improves overall survival (OS) and progression-free survival (PFS) in hepatocellular carcinoma (HCC). Whether adding on-demand transcatheter arterial chemoembolization (TACE) to Atezo/Bev (ABC-TACE) adds benefit, and whether this depends on the tumor response already achieved, remains unclear.

Methods

We retrospectively analyzed 567 patients with unresectable HCC given Atezo/Bev at 16 Japanese institutions. Those who underwent on-demand TACE during Atezo/Bev treatment formed the ABC-TACE group (n = 90) and those who did not the Atezo/Bev-alone control group (n = 477). Because TACE was performed at a variable time (median 199 days after initiation), the primary analysis entered TACE as a time-dependent covariate, with landmark analyses at 3, 6, and 9 months. An exploratory analysis stratified the cohort by the response documented before TACE: partial response (PR), stable disease (SD) with or without shrinkage, and progressive disease (PD). Adverse events were graded by CTCAE v5.0, and the albumin-bilirubin (ALBI) score was compared by mixed-effects modeling.

Results

Adjusted for ten prespecified covariates, TACE was associated with longer OS (hazard ratio [HR] = 0.48, 95% confidence interval [CI]: 0.32–0.71; p < 0.001) and PFS (HR = 0.62, 95% CI: 0.42–0.92; p = 0.018). Assigning exposure at any time, which ignores immortal time, gave HRs of 0.37 and 0.34. Landmark analyses were concordant in direction. Grade ≥3 adverse events (27.8% versus 35.2%; p = 0.184) and ALBI trajectories (ever- vs never-TACE; p = 0.198) did not differ significantly. Stratified by pre-TACE response (exploratory), OS HRs were 0.12 for PR, 0.42 and 0.53 for the two SD strata, and 1.51 for PD (interaction p = 0.020). The estimates are imprecise (only 2 deaths in the PR stratum followed embolization), the interaction did not persist when the PD stratum was excluded (p = 0.097), and PFS showed no corresponding interaction (p = 0.589).

Conclusion

In this real-world cohort, ABC-TACE was associated with longer survival than Atezo/Bev alone. The response-stratified analyses are exploratory and do not establish effect modification. These findings are hypothesis-generating rather than practice-changing, and prospective response-stratified evaluation is required before a response-guided approach can be adopted.

Zitieren

APA

Kuroda, H., Sho, T., Suda, G., Ninomiya, M., Abe, T., Endo, K., Watanabe, T., Fujiwara, Y., Sasaki, T., Yoshida, Y., Kakisaka, K., Oikawa, T., Sawara, K., Tsuruoka, M., Numao, H., Igarashi, G., Iino, C., Yoshida, K., Sato, S., …, & Matsumoto, T. (2026). Survival Benefit of Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Liver Cancer. https://doi.org/10.1159/lic/admag030

Vancouver

Kuroda H, Sho T, Suda G, Ninomiya M, Abe T, Endo K, et al. Survival Benefit of Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Liver Cancer. 2026. doi:10.1159/lic/admag030

BibTeX
@article{Kuroda2026,
  author = {Kuroda, Hidekatsu and Sho, Takuya and Suda, Goki and Ninomiya, Masashi and Abe, Tamami and Endo, Kei and Watanabe, Takuya and Fujiwara, Yudai and Sasaki, Tokio and Yoshida, Yuichi and Kakisaka, Keisuke and Oikawa, Takayoshi and Sawara, Kei and Tsuruoka, Mio and Numao, Hiroshi and Igarashi, Go and Iino, Chikara and Yoshida, Kenta and Sato, Satoshi and Katsumi, Tomohiro and Maki, Keita and Sato, Wataru and Minami, Shinichiro and Abe, Kazumichi and Fujita, Masashi and Tanabe, Nobukazu and Yamamoto, Yoshiya and Baba, Masaru and Meguro, Takashi and Sakamoto, Naoya and Ueno, Yoshiyuki and Matsumoto, Takayuki},
  title = {Survival Benefit of Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study},
  journal = {Liver Cancer},
  year = {2026},
  doi = {10.1159/lic/admag030}
}
Kostenlos starten →